Morgan Stanley
BMGL

Morgan Stanley’s Basel Medical BMGL Stock Holding History

Morgan Stanley’s Portfolio BMGL Stock Details BMGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-6,191
Closed -$135K – 8558
2025
Q3 		$135K Buy
+6,191
New +$155K ﹤0.01% 6036

Other funds holding BMGL

GSC
Ground Swell Capital Folly Beach, South Carolina $92.6M AUM 41.64% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
BIA
Bell Investment Advisors Oakland, California $681M AUM 18.36% 1-Year Est. Return

Morgan Stanley's BMGL Position: Q4 2025 in Review

Morgan Stanley sold out of Basel Medical (BMGL) in Q4 2025, closing a stake of 6,191 shares — an estimated $135K sold.

Morgan Stanley first reported a position in BMGL in Q3 2025 and held it in 1 quarter. The position peaked at $135K in Q3 2025. 9 funds tracked by Wall St. Rank hold BMGL as of Q4 2025.

  • Morgan Stanley reported no remaining Basel Medical position as of Q4 2025 after selling out during the quarter.
  • Morgan Stanley sold 6,191 Basel Medical shares in Q4 2025, an estimated $135K.
  • Morgan Stanley first reported a position in Basel Medical in Q3 2025 and held it in 1 quarter.
  • Morgan Stanley's Basel Medical position peaked at $135K in Q3 2025.
  • 9 funds tracked by Wall St. Rank held Basel Medical as of Q4 2025.

Based on Morgan Stanley's 13F filing for Q4 2025, filed 13 Feb 2026.